[Clinical studies on clindamycin-2-phosphate in the field of surgery (author's transl)].
Twenty eight patients were treated with parenteral clindamycin-2-phosphate in the field of surgery, and good response was obtained in a series of superficial soft tissue infection, especially caused by staphylococci, with a daily dose of 300 mg. Serum level and urinary excretion were also investigated in four healthy male volunteers.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy; D002056:Burns / Q000188:drug therapy; D002481:Cellulitis / Q000188:drug therapy; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D005667:Furunculosis / Q000188:drug therapy; D006801:Humans; D008199:Lymphadenitis / Q000188:drug therapy; D008297:Male; D008413:Mastitis / Q000188:drug therapy; D008875:Middle Aged; D009943:Organophosphorus Compounds; D010304:Paronychia / Q000188:drug therapy; D011247:Pregnancy; D012505:Sarcina / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy
D009943:Organophosphorus Compounds; D002981:Clindamycin